MAIA Biotechnology
MAIA
33 hedge funds and large institutions have $18.4M invested in MAIA Biotechnology in 2026 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 6 closing their positions.
13,345% more capital inflows, than outflows
Capital inflows: $21.9M | Capital outflows: $163K
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
27% more funds holding
Funds holding: 26 → 33 (+7)
14.88% more ownership
Funds ownership: 6.8% → 21.68% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Solas Capital Management
Darien,
Connecticut
|
+$7.92M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$4.61M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.97M |
| 4 |
Cable Car Capital
San Francisco,
California
|
+$1.2M |
| 5 |
Bleichroeder LP
New York
|
+$922K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$120K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.9K |
| 3 |
StoneX Group
New York
|
-$15.7K |
| 4 |
Citigroup
New York
|
-$3.16K |
| 5 |
SRH Advisors
Salina,
Kansas
|
-$999 |
MAIA Hedge Fund Activity: Q1 2026 in Review
33 of the 8,226 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q1 2026, worth a combined $18.4M — up 350% from $4.09M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MAIA positions and 6 closed out — a net gain of 8 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Solas Capital Management, opening a new position worth an estimated $7.92M. The largest seller was Jane Street, exiting entirely with an estimated $120K sold.
- 33 institutional investors held MAIA Biotechnology (MAIA) as of Q1 2026, up from 26 in Q4 2025.
- Funds reported $18.4M of MAIA Biotechnology stock for Q1 2026, up 350% quarter-over-quarter.
- 14 funds opened new MAIA Biotechnology positions in Q1 2026 and 6 closed out, a net change of +8 holders.
- The largest MAIA Biotechnology buyer in Q1 2026 was Solas Capital Management, an estimated $7.92M added.
- The largest MAIA Biotechnology seller in Q1 2026 was Jane Street, an estimated $120K sold.
Based on aggregated 13F filings for Q1 2026.